A new under-the-skin injectable formulation of Vyvgart (efgartigimod alfa) has been approved by the European Commission for adults with…
Marisa Wexler, MS
senior science writer
Marisa Horak joined Bionews in 2018 right after she completed her master’s degree in cellular and molecular pathology. She has dedicated her career to making scientific and medical information more accessible to people affected by rare and chronic disorders.
Education
- MS, Cellular and Molecular Pathology, University of Pittsburgh
- BS, Microbiology, Michigan State University
Professional Accomplishments
- Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways, 2019, Briefings in Bioinformatics
- Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity, 2018, Oncotarget
- Insights on processes of evolutionary tumor growth, 2016, Atlas Genet Cytogenet Oncol Haematol
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Kyverna Therapeutics, giving…
The U.S. Food and Drug Administration (FDA) has given Cabaletta Bio the go-ahead to launch a Phase 1/2 clinical…
The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under…
A treatment based on GRO Biosciences‘ ProGly program — which uses specially designed proteins to regulate the immune system…
UCB’s zilucoplan and Rystiggo (rozanolixizumab) both were approved in Japan to treat adults with generalized myasthenia gravis…
Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according…
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments,…
Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first…
The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17,…